RU94006023A - Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения - Google Patents

Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения

Info

Publication number
RU94006023A
RU94006023A RU94006023/04A RU94006023A RU94006023A RU 94006023 A RU94006023 A RU 94006023A RU 94006023/04 A RU94006023/04 A RU 94006023/04A RU 94006023 A RU94006023 A RU 94006023A RU 94006023 A RU94006023 A RU 94006023A
Authority
RU
Russia
Prior art keywords
cyclodextrin
protein
polyalkylene oxide
physiologically active
lyophilized
Prior art date
Application number
RU94006023/04A
Other languages
English (en)
Inventor
П.Филлипс Кристофер
Us]
А.Сноу Роберт
Original Assignee
Стерлинг Уинтроп Инк. (US)
Стерлинг Уинтроп Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стерлинг Уинтроп Инк. (US), Стерлинг Уинтроп Инк. filed Critical Стерлинг Уинтроп Инк. (US)
Publication of RU94006023A publication Critical patent/RU94006023A/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В изобретении раскрывается водная физиологически активная белковая композиция для лиофилизации, включающая: от 150 до 150000 ед/мл ковалентно связанного низкого диол полиалкилен оксида/белка, предпочтительно полиэтиленгликоля/белка; от 0,1 до 20 вес.%/об. циклодекстрина, предпочтительно бета-циклодекстрина; и от 0,01 до 50 мм буфера, рН от 5,7 до 6,5, вместе со способом ее получения и использованием в производстве лекарств для лечения состояния заболевания, вызванного анионами супероксида в тканях млекопитающих.

Claims (1)

  1. В изобретении раскрывается водная физиологически активная белковая композиция для лиофилизации, включающая: от 150 до 150000 ед/мл ковалентно связанного низкого диол полиалкилен оксида/белка, предпочтительно полиэтиленгликоля/белка; от 0,1 до 20 вес.%/об. циклодекстрина, предпочтительно бета-циклодекстрина; и от 0,01 до 50 мм буфера, рН от 5,7 до 6,5, вместе со способом ее получения и использованием в производстве лекарств для лечения состояния заболевания, вызванного анионами супероксида в тканях млекопитающих.
RU94006023/04A 1993-02-25 1994-02-24 Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения RU94006023A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/023,182 US5298410A (en) 1993-02-25 1993-02-25 Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US023182 1993-02-25

Publications (1)

Publication Number Publication Date
RU94006023A true RU94006023A (ru) 1996-04-20

Family

ID=21813561

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94006023/04A RU94006023A (ru) 1993-02-25 1994-02-24 Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения

Country Status (18)

Country Link
US (4) US5298410A (ru)
EP (1) EP0614666A1 (ru)
JP (1) JPH06256222A (ru)
KR (1) KR940019312A (ru)
AU (1) AU660843B2 (ru)
CA (1) CA2106519A1 (ru)
CZ (1) CZ38194A3 (ru)
FI (1) FI940909A (ru)
HU (1) HUT71586A (ru)
IL (1) IL108777A (ru)
MX (1) MX9305528A (ru)
MY (1) MY131553A (ru)
NO (1) NO940663L (ru)
NZ (1) NZ248590A (ru)
PH (1) PH30462A (ru)
RU (1) RU94006023A (ru)
SK (1) SK23294A3 (ru)
TW (1) TW260611B (ru)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031920A1 (fr) * 2007-08-22 2009-03-12 Company Limited 'concern O3' Médicament hypoglycémique et procédé de fabrication
WO2009045122A1 (fr) * 2007-10-05 2009-04-09 Company Limited 'concern O3' Médicament destiné au traitement et à la prévention des complications liées au diabète sucré
WO2009045123A1 (fr) * 2007-10-05 2009-04-09 Company Limited 'concern O3' Médicament possédant un effet stimulant l'hématopoïèse et hépatoprotecteur
RU2452509C1 (ru) * 2011-01-31 2012-06-10 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" ООО "Саентифик Фьючер Менеджмент" Средство для стимуляции роста организма

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
CA2114163C (en) * 1993-01-29 2002-04-30 Nobuo Nishiki Method for stabilizing antigenicity of myeloperoxidase
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (fr) * 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JPH0776700A (ja) * 1993-07-14 1995-03-20 Senju Pharmaceut Co Ltd コンタクトレンズ用剤の安定化方法
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5856451A (en) * 1994-12-07 1999-01-05 Novo Nordisk A/S Method for reducing respiratory allergenicity
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5861148A (en) * 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
EP0816381B1 (en) * 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Polyethylene glycol modified hepatocyte growth factor (hgf)
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5868868A (en) * 1995-06-19 1999-02-09 Alcon Laboratories, Inc. Peg-modified proteases and methods of use in contact lens cleaning
BR9510676A (pt) * 1995-12-29 1999-11-23 Procter & Gamble Composições detergentes compreendendo enzinas imobilizadas
WO1997039761A1 (en) * 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
DE69713517D1 (de) 1996-10-15 2002-07-25 Medical Analysis Systems Inc Verfahren zur Stabilisierung von Troponin I (CTnI) durch Konjugation mit einem activen Polymer
WO1998035551A1 (en) * 1997-02-13 1998-08-20 Lxr Biotechnology Inc. Organ preservation solution
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
GB9815785D0 (en) * 1998-07-20 1998-09-16 Cerebrus Ltd Chemical compounds
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
PL200586B1 (pl) * 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
AU762616B2 (en) 1998-10-16 2003-07-03 Biogen Ma Inc. Polymer conjugates of interferon beta-1a and uses
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1282411A4 (en) * 2000-04-26 2008-05-21 Charlotte Mecklenburg Hospital ANTICANCER TREATMENT METHOD
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
SG98393A1 (en) * 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US7195923B2 (en) * 2001-01-31 2007-03-27 Scripps Laboratories, Inc. Ratiometric determination of glycated protein
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2002094324A1 (en) * 2001-05-18 2002-11-28 Institute Of Materials Research & Engineering Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DE60223047T2 (de) 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal Verfahren zur herstellung von aktivierten polyethylenglykolen
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20050132430A1 (en) * 2001-12-21 2005-06-16 Mogens Baltsen Igamete recruitment and developmental competence in mammals by inhibiting the de-nova sterol biosynthesis and/or promoting sterol efflux
CN1620499A (zh) * 2001-12-21 2005-05-25 哥本哈根大学医院 哺乳动物的配子募集和发育能力－通过抑制固醇从头生物合成和/或促进固醇外流
GEP20074024B (en) 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
EP1476492A1 (en) * 2002-02-22 2004-11-17 Insert Therapeutics Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
EP2266590A3 (en) * 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
ES2500117T3 (es) * 2002-02-22 2014-09-30 Shire Llc Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
KR101476067B1 (ko) 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
PT1644019E (pt) * 2003-05-29 2012-05-23 Shire Llc Compostos de anfetamina resistentes ao abuso
PT1656410E (pt) 2003-07-22 2010-06-11 Nektar Therapeutics Processo para preparação de polímeros funcionalizados a partir de álcoois poliméricos
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN102895666B (zh) * 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006013921A1 (ja) * 2004-08-05 2006-02-09 Asahi Kasei Pharma Corporation プロテアーゼ反応促進剤及び／又は色素の安定化剤を含む試薬
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
RU2435847C2 (ru) 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
WO2006119280A2 (en) * 2005-05-03 2006-11-09 Handylab, Inc. Lyophilized pellets
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
EP2412744B1 (en) 2005-07-18 2014-01-22 Nektar Therapeutics Method for preparing branched functionalised polymers using branched polyol cores
KR100664969B1 (ko) * 2005-08-26 2007-01-04 아이디비켐(주) 고순도의 메톡시폴리에틸렌글리콜 및 그들의 유도체의제조방법
CN100360666C (zh) * 2005-11-29 2008-01-09 沈阳农业大学 一种修饰玉米sod的方法
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US20070173634A1 (en) * 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
WO2008101311A1 (en) * 2007-02-22 2008-08-28 Biovectra Inc. Process for purification of water soluble polymers
JP4697809B2 (ja) * 2007-02-22 2011-06-08 旭化成ファーマ株式会社 ロイコ色素の安定化方法
BRPI0818004B8 (pt) * 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
JP5569787B2 (ja) * 2009-03-31 2014-08-13 日油株式会社 高分子量ポリエチレングリコール化合物の精製方法
JP5713274B2 (ja) * 2009-03-31 2015-05-07 日油株式会社 高分子量ポリオキシアルキレン誘導体の精製方法
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트
EP2503888A4 (en) * 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
US8163869B1 (en) 2010-12-27 2012-04-24 Nof Corporation Purification method of carboxyl group-containing polyoxyethylene derivative
US9090769B2 (en) 2011-04-05 2015-07-28 Ticona Llc Molded articles having a swirl-like or marble-like appearance and compositions for producing same
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
JP7177392B2 (ja) * 2018-03-29 2022-11-24 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法
WO2019234632A1 (en) * 2018-06-07 2019-12-12 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN109206598A (zh) * 2018-09-10 2019-01-15 武汉轻工大学 聚乙二醇-聚丙交酯嵌段共聚物的制备方法以及药物载体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
US4970216A (en) * 1986-03-17 1990-11-13 Richardson Vicks, Inc. Skin treatment composition and method
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5183809A (en) * 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5182270A (en) * 1989-08-03 1993-01-26 Iolab Corporation Stabilizing preparation for thymoxamine
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5145644A (en) * 1990-12-20 1992-09-08 Allergan, Inc. Hydrogen peroxide destroying compositions and methods of making and using same
JPH04248984A (ja) * 1991-02-05 1992-09-04 Kuraray Co Ltd スーパーオキシドジスムターゼ誘導体およびその製造方法
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031920A1 (fr) * 2007-08-22 2009-03-12 Company Limited 'concern O3' Médicament hypoglycémique et procédé de fabrication
WO2009045122A1 (fr) * 2007-10-05 2009-04-09 Company Limited 'concern O3' Médicament destiné au traitement et à la prévention des complications liées au diabète sucré
WO2009045123A1 (fr) * 2007-10-05 2009-04-09 Company Limited 'concern O3' Médicament possédant un effet stimulant l'hématopoïèse et hépatoprotecteur
RU2452509C1 (ru) * 2011-01-31 2012-06-10 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" ООО "Саентифик Фьючер Менеджмент" Средство для стимуляции роста организма

Also Published As

Publication number Publication date
NO940663L (no) 1994-08-26
MY131553A (en) 2007-08-30
US5529915A (en) 1996-06-25
CZ38194A3 (en) 1994-10-19
AU4616293A (en) 1994-09-01
EP0614666A1 (en) 1994-09-14
US5389381A (en) 1995-02-14
TW260611B (ru) 1995-10-21
NO940663D0 (no) 1994-02-25
US5334382A (en) 1994-08-02
HU9400561D0 (en) 1994-05-30
AU660843B2 (en) 1995-07-06
FI940909A (fi) 1994-08-26
PH30462A (en) 1997-05-28
IL108777A0 (en) 1994-06-24
KR940019312A (ko) 1994-09-14
US5298410A (en) 1994-03-29
NZ248590A (en) 1995-07-26
HUT71586A (en) 1995-12-28
JPH06256222A (ja) 1994-09-13
SK23294A3 (en) 1995-02-08
FI940909A0 (fi) 1994-02-25
CA2106519A1 (en) 1994-08-26
IL108777A (en) 1998-02-08
MX9305528A (es) 1994-08-31

Similar Documents

Publication Publication Date Title
RU94006023A (ru) Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения
US4824938A (en) Water-soluble dry solid containing proteinaceous bioactive substance
CA2269519C (en) Acylated cyclodextrin derivatives
EP1372735B1 (de) Hydroxyalkylstärke-wirkstoff-konjugate
US6011008A (en) Conjugates of biologically active substances
CA2532475C (en) Formulation for a protein pharmaceutical without added human serum albumin (hsa)
JP4606587B2 (ja) ポリサッカライドと結合した治療ペプチドの滅菌複合体
RU2349347C2 (ru) Повязки на рану, содержащие белковый полимер и полифункциональный спейсер
US9187529B2 (en) Cationic peptides and use of such peptides for inhibiting exotoxin production
WO1990000397A1 (en) A pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
JPH11500404A (ja) ポリペプチド、特にタンパク質の可溶化および安定化のための方法および組成物
WO1990015628A1 (en) Polymer/antibiotic conjugate
WO1999042126A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
JPS62255435A (ja) 安定性タンパク質及びタンパク質の安定化法
JP2005527470A5 (ru)
EP1126881B1 (de) Mucoadhäsive polymere, deren verwendung sowie deren herstellungsverfahren
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
RU94042935A (ru) Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав
HU210901A9 (en) Polymyxin conjugates
EP0325270A2 (en) Anticancer conjugates
WO2016183277A1 (en) Materials for tissue regeneration
EP1459738B1 (en) Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties
US20040110678A1 (en) Novel drug delivery system
JP5778692B2 (ja) 疾病抑制剤
EP0114685B1 (en) Fibronectin complexes